ARQTArcutis Biotherapeutics
Smart Score
How it is scored →The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.
Compared with: Health care companies in USA (n = 211)
Current rating first published: · last recomputed · rating log
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Gross profit growth / assets (5 y)supports the score · percentile 94
- Gross profit / assetssupports the score · percentile 97
- Share issuance (1 y)weighs on the score · percentile 18
Red flags and notes
- Serious warning:Heavy dilution Share count growing more than 10 % a year over three years.
- Caution:Cash burn Negative free cash flow in at least two of the last three years.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/E
- 116,4
- P/B
- 15,0
- P/S
- 7,2
- EV/EBIT
- 93,1
- Free-cash-flow yield
- 1,2%
- Market cap (EUR)
- 3 млрд €
Profitability and debt
- Return on equity
- 15,9%
- Return on invested capital
- 14,6%
- Gross margin
- 91,1%
Dividends
- Dividend yield
- 0,00%
- Years of dividend growth
- 0
Returns and risk
- 1 day
- +1,2%
- 1 month
- +8,8%
- 1 year
- +29,3%
- Volatility, 1 yr
- 55,2%
- Max drawdown, 1 yr
- −37,5%
- Beta
- 0,85
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
News and filings
- Arcutis Biotherapeutics, Inc.: 10-Q — Quarterly report for the period ending 2026-06-30
FactSEC EDGAR · Filing · 6 серп. 2026
- Arcutis Biotherapeutics, Inc.: 8-K — Results of operations; director or officer change
FactSEC EDGAR · Filing · 6 серп. 2026
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| First rating | 2/10 | 2 · — | Serious warning:Heavy dilutionCaution:Cash burn | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Вийти з контракту тут · Споживачі ЄС: 14 днів на відмову від покупки.